Pyruvate is an intermediate of energy metabolism and was shown to possess pronounced positive inotropic effects in vitro and in vivo without altering myocardial oxygen consumption. Moreover, it was shown that the effects of beta-adrenergic stimulation were potentiated. Thus, it might be possible to save catecholamines in patients with severe heart failure or cardiogenic shock. This study was designed to test the hemodynamic effects of pyruvate administered into a coronary artery in addition to intra-aortic balloon pump counterpulsation in patients with severe heart failure or in patients with acute myocardial infarction and cardiogenic shock after having performed percutaneous coronary intervention. A pronounced improvement in hemodynamics is expected to occur.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
8
sodium pyruvate 300 mmol/L, 360 mL/h i.c. over 30 minutes.
Herzzentrum Goettingen, Cardiology and Pneumology
Göttingen, Germany
Cardiac Output
Time frame: 60 minutes
Cardiac Index
Time frame: 60 minutes
Arterial Pressure
Time frame: 60 minutes
Pulmonary capillary wedge pressure
Time frame: 60 minutes
Pulmonary artery pressure
Time frame: 60 minutes
systemic vascular resistance
Time frame: 60 minutes
pulmonary vascular resistance
Time frame: 60 minutes
heart rate
Time frame: 60 minutes
stroke volume
Time frame: 60 minutes
catecholamine need
Time frame: 60 minutes
safety
Time frame: 60 minutes
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.